Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.39 |
| ▸ | JAK3 | P52333 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664056 | 0.82 | MKNK1 (0.48) | NNMTIRAK4JAK3JAK2JAK1 | |
| SCHEMBL29127194 | 0.82 | MKNK1 (0.48) | NNMTIRAK4JAK3JAK2JAK1 | |
| SCHEMBL2479053 | 0.78 | KDM4E (0.51) | IRAK4MAPK8JAK3JAK2JAK1 | |
| SCHEMBL21596321 | 0.78 | NNMT (0.41) | NNMTIRAK4JAK3JAK2JAK1 | |
| SCHEMBL30379577 | 0.78 | NNMT (0.41) | NNMTIRAK4JAK3JAK2JAK1 | |
| SCHEMBL2479527 | 0.78 | JAK3 (0.53) | IRAK4MAPK8JAK3JAK2JAK1 | |
| SCHEMBL12281913 | 0.77 | NNMT (0.57) | NNMTIRAK4JAK3JAK2JAK1 | |
| SCHEMBL30678683 | 0.77 | NNMT (0.57) | NNMTIRAK4JAK3JAK2JAK1 | |
| SCHEMBL12456545 | 0.77 | JAK3 (0.52) | IRAK4JAK3JAK2JAK1TYK2 | |
| SCHEMBL18345047 | 0.77 | IRAK4 (0.34) | IRAK4MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-8309721-B2 | HSP90 inhibitory carbazole derivatives, compositions containing same and use thereof | SANOFI (FR) | 2012-11-13 | — | — | US | disclosed |
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | US | disclosed |
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | US | disclosed |
| WO-2009122034-A2 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166169-A1 | NOVEL HSP90 INHIBITORY CARBAZOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | NNMT 2289/4885IRAK4 3961/4885MAPK8 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.